Novo taps bluebird bio for gene-editing tech

Looking to further broaden its reach outside of diabetes, Novo Nordisk has teamed up with bluebird bio to treat a series of genetic diseases.

The pair will over a three-year R&D pact develop next-gen in vivo genome-editing treatments for genetic diseases, with hemophilia being an early focus.

Financial details of the pact were not disclosed.